A person with neuroblastoma, which occurs when developing nerve cells in children turn cancerous, has remained tumour-free ...
The probe is directed at all CAR-Ts currently ... positive lymphoma – in patients who had received both types of CAR-T therapy. The regulator highlighted the products by name, including Bristol- ...
An 18-year survivor of neuroblastoma, a solid childhood tumor that develops in immature nerve cells, is believed to represent ...
A patient has achieved over 18 years of remission from neuroblastoma, a type of nerve cell cancer, following treatment with ...
TG Therapeutics will use MaxCyte’s technology to advance toward a clinical trial its azer-cel CAR T-cell therapy for progressive forms of MS.
The off-the-shelf chimeric antigen receptor T-cell therapy P-BCMA-ALLO1 was shown to be safe and elicited strong anti-tumor ...
Researchers sought to determine whether the CAR-T therapy volamcabtagene durzigedleucel (CTX130) would be effective in patients with T-cell lymphoma.
CAR T-cell therapy for cancer leads to similar safety and cancer outcomes in patients with and without preexisting autoimmune ...
Like other CAR-Ts, Calibr's therapy is manufactured from a patient's own T-cells, which are harvested and genetically modified to fight cancer before being reintroduced into the body. However ...
Bristol Myers Squibb (BMS) has reported that the multi-centre Phase II TRANSCEND FL trial assessing its cluster of ...
Treatment with the CAR-T cell therapy Yescarta (axicabtagene ciloleucel) continued to demonstrate durable responses after a median follow-up of more than five years in patients with ...
NEW DELHI: India’s first global CAR T-cell therapy for adult B-cell Non-Hodgkin Lymphoma (B-NHL), a kind of blood cancer that affects the lymphatic system, has been launched in the country ...